¼¼°è ¹æ»ç¼± Ä¡·á ½ÃÀåÀº 2024³â¿¡´Â 74¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, 2034³â¿¡´Â CAGR 5.9%·Î ¼ºÀåÇÏ¿© 130¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
À̰ÍÀº Á¾¾çÀ» Ãà¼Ò½ÃŰ°Å³ª ¾Ï¼¼Æ÷¸¦ Á¦°ÅÇϱâ À§ÇØ °í¼±·®ÀÇ ¹æ»ç¼±À» »ç¿ëÇÏ´Â ¾Ï Ä¡·á°¡ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ Ä¡·á¹ýÀº ¾Ï¼¼Æ÷ÀÇ DNA¿¡ µ¥¹ÌÁö¸¦ ÁÖ¾î ºÐ¿À̳ª Áõ½ÄÀ» ¹æÇØÇÔÀ¸·Î½á ±â´ÉÇÕ´Ï´Ù.
½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº ¹æ»ç¼± Ä¡·á¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¾Ï Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÏ¹Ý ½Ã¹ÎÀÇ ÀǽÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Ä¡·á(IGRT), ¾çÀÚ¼± Ä¡·á µîÀÇ ±â¼ú Áøº¸¿¡ ÀÇÇØ ¹æ»ç¼± Ä¡·áÀÇ Á¤¹Ðµµ°¡ ´ëÆø Çâ»óµÇ¾î, °Ç°ÇÑ Á¶Á÷À» ¿ÂÁ¸ÇÏ¸é¼ ¾Ï¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î ÇÒ ¼ö ÀÖ°Ô µÇ¾î ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ±â°£ | 2025-2034³â |
Ãʱ⠽ÃÀå ±Ô¸ð | 74¾ï ´Þ·¯ |
½ÃÀå ±Ô¸ð ¿¹Ãø | 130¾ï ´Þ·¯ |
CAGR | 5.9% |
¿ÜºÎ Á¶»ç ¹æ»ç¼± ¿ä¹ý ºÐ¾ß´Â 2024³â 48¾ï ´Þ·¯ÀÇ ¸ÅÃâÀ» ±â·ÏÇßÀ¸¸ç 2034³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 5.9%·Î ¼ºÀåÀ» °è¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¼ºÀåÀº ÁÖ·Î À¯¹æ¾Ï, Àü¸³¼±¾Ï, Æó¾Ï, ´ëÀå¾Ï µî ´Ù¾çÇÑ À¯ÇüÀÇ Çѱ¹¼º ¾Ï ¹ß»ý·üÀÌ »ó½ÂÇϰí ÀÖ´Â °Í¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù.
º´¿ø ºÐ¾ß´Â ¸®´Ï¾ÇÀ̳ª ¾çÀÚ¼± Ä¡·á ½Ã½ºÅÛ µîÀÇ ¼±ÁøÀûÀÎ ¹æ»ç¼± Ä¡·á ±â¼úÀÌ ÀÌ¿ë °¡´ÉÇϱ⠶§¹®¿¡ 2024³â¿¡ 31¾ï ´Þ·¯¸¦ ¸¸µé¾î ³Â½À´Ï´Ù. º´¿øÀº ¾Ï Ä¡·á¸¦ À§ÇÑ Á¾ÇÕ ¼¾Åͷμ ÈÇÐ ¿ä¹ý, ¸é¿ª ¿ä¹ý, ¼ö¼ú°ú °°Àº ´Ù¾çÇÑ Ä¡·á¹ýÀ» Á¦°øÇÕ´Ï´Ù.
¹Ì±¹ÀÇ ¹æ»ç¼± Ä¡·á ½ÃÀåÀº Àü¹Ì¿¡¼ÀÇ ¾Ï ÀÌȯÀ²ÀÇ »ó½Â¿¡ °ßÀεǾî 2024³â¿¡´Â 25¾ï ´Þ·¯¸¦ âÃâÇß½À´Ï´Ù. °¡Àå È¿°úÀûÀÌ°í ³Î¸® »ç¿ëµÇ´Â ¹æ¹ý Áß Çϳª´Â ¹æ»ç¼± Ä¡·áÀÇ È¿´É¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁø °Í ¿Ü¿¡µµ ±ÙÄ¡Àû Ä¡·á¿Í ¿ÏÈ Ä¡·á ¸ðµÎ¿¡¼ ¹æ»ç¼± Ä¡·áÀÇ ¿ªÇÒÀÌ ¹æ»ç¼± Ä¡·áÀÇ Ã¤Åÿ¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¹æ»ç¼± Ä¡·á ½ÃÀåÀÇ À¯·Â ±â¾÷Àº ¸Þºñ¿Â ¸ÞµðÄà ½Ã½ºÅÛÁî, Accuray, µµ½Ã¹Ù ¿¡³ÊÁö ½Ã½ºÅÛ ¹× ¼Ö·ç¼Ç, Brainlab, ¹Ì¾²ºñ½Ã Àü±â, IBA Radiopharma Solutions, Isoray Inc., È÷Ÿġ ÇÏÀÌÅ×Å©, RefleXion, Curium, Elekta, Canon Medical Systems, Nordion, NTP Radioisotopes Systems µîÀÌ ÀÖ½À´Ï´Ù. ½ÃÀå Æ÷Áö¼ÇÀ» °ÈÇϱâ À§ÇØ ¹æ»ç¼± Ä¡·á ¾÷°è¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ±â¾÷Àº Á¦Ç° Æ÷Æ®Æú¸®¿ÀÀÇ È®´ë¿Í ±â±âÀÇ ±â¼ú·Â Çâ»ó¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¿ì¸®´Â ¾çÀÚ¼± Ä¡·á ±â´É µîÀÇ ¼±Áø ±â´ÉÀ» ÅëÇÕÇÑ Çõ½ÅÀûÀÎ ¹æ»ç¼± Ä¡·á ½Ã½ºÅÛÀÇ °³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.
The Global Radiotherapy Market was valued at USD 7.4 billion in 2024 and is estimated to grow at a CAGR of 5.9% to reach USD 13 billion by 2034, driven by the treatment for cancer that involves the use of high doses of radiation to shrink tumors or eliminate cancer cells. It works by damaging the DNA of the cancer cells, preventing them from dividing and growing. There are two primary types of radiotherapy: internal, known as brachytherapy, where radioactive material is placed inside the body near the tumor, and external, where an external beam of radiation is directed at the cancer using equipment like linear accelerators.
The market growth is primarily driven by increased public awareness about various cancer treatment options, including radiotherapy. Numerous government and non-profit organizations run awareness campaigns to educate the public on the importance of early cancer detection and treatment options. Additionally, technological advancements such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and proton therapy are significantly improving the precision of radiotherapy, allowing for the targeting of cancerous cells while sparing healthy tissues. These innovations are making radiotherapy an increasingly preferred treatment option for cancer patients.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $7.4 Billion |
Forecast Value | $13 Billion |
CAGR | 5.9% |
The external beam radiation therapy segment generated USD 4.8 billion in 2024 and is expected to continue its growth at a CAGR of 5.9% through 2034. This growth is mainly attributed to the rising incidence of various types of localized cancers, including breast, prostate, lung, and colon cancers. The increasing adoption of advanced proton therapy, a form of external beam radiotherapy, contributes to the segment's expansion.
The hospital segment generated USD 3.1 billion in 2024 due to the availability of advanced radiotherapy technologies such as linear accelerators and proton therapy systems. Hospitals serve as comprehensive centers for cancer treatment, offering various therapies like chemotherapy, immunotherapy, and surgeries. The collaboration between hospitals and manufacturers to develop and implement cutting-edge radiotherapy equipment has further fueled the segment's growth.
U.S. Radiotherapy Market generated USD 2.5 billion in 2024 driven by the rising cancer incidence across the country. As the number of cancer diagnoses continues to increase, there is a growing demand for advanced treatment options, with radiotherapy being one of the most effective and widely used methods. The increasing awareness of radiotherapy's effectiveness, along with its role in both curative and palliative treatments, has further contributed to its adoption.
Prominent players in the Radiotherapy Market include Mevion Medical Systems, Accuray, Toshiba Energy Systems and Solutions, Brainlab, Mitsubishi Electric, IBA Radiopharma Solutions, Isoray Inc., Hitachi High-Tech, RefleXion, Curium, Elekta, Canon Medical Systems, Nordion, NTP Radioisotopes, Varian Medical Systems. To strengthen their market position, companies operating in the radiotherapy industry are focusing on expanding their product portfolios and improving the technological capabilities of their equipment. Many market players are investing in developing innovative radiotherapy systems that integrate advanced features such as precision imaging, real-time guidance, and proton therapy capabilities. Collaborations between manufacturers and healthcare facilities are rising to improve the accessibility of state-of-the-art technologies in treatment centers.